Rationale for the clinical guidelines for myasthenia gravis in Japan

Hiroyuki Murai, Kimiaki Utsugisawa, Yuriko Nagane, Shigeaki Suzuki, Tomihiro Imai, Masakatsu Motomura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients' health-related quality of life. Therefore, the initial treatment goal is defined as maintaining a postintervention status of minimal manifestations or better (according to the Myasthenia Gravis Foundation of America classification) with an oral prednisolone dose of 5 mg/day or less. Every effort should be made to attain this level as rapidly as possible. To achieve this goal, the guidelines recommend minimizing the oral prednisolone dose, starting calcineurin inhibitors early in the course of treatment, using intravenous methylprednisolone infusion judiciously (often combined with plasma exchange/plasmapheresis or intravenous immunoglobulin), and effectively treating patients with an early, fast-acting treatment strategy. The early, fast-acting treatment strategy enables more frequent and earlier attainment of the initial goal than other strategies. Thymectomy is considered an option for treating nonthymomatous early-onset myasthenia gravis in patients with antiacetylcholine receptor antibodies and thymic hyperplasia in the early stages of the disease.

Original languageEnglish
JournalAnnals of the New York Academy of Sciences
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Myasthenia Gravis
Prednisolone
Japan
Guidelines
Intravenous Immunoglobulins
Methylprednisolone
Health
Plasmas
Thymus Hyperplasia
Antibodies
Therapeutics
Thymectomy
Plasma Exchange
Plasmapheresis
Intravenous Infusions
Quality of Life
Calcineurin Inhibitors
Dose

Keywords

  • Clinical guidelines
  • Corticosteroids
  • Immunosuppressants
  • Myasthenia gravis
  • Thymectomy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Rationale for the clinical guidelines for myasthenia gravis in Japan. / Murai, Hiroyuki; Utsugisawa, Kimiaki; Nagane, Yuriko; Suzuki, Shigeaki; Imai, Tomihiro; Motomura, Masakatsu.

In: Annals of the New York Academy of Sciences, 01.01.2018.

Research output: Contribution to journalArticle

Murai, Hiroyuki ; Utsugisawa, Kimiaki ; Nagane, Yuriko ; Suzuki, Shigeaki ; Imai, Tomihiro ; Motomura, Masakatsu. / Rationale for the clinical guidelines for myasthenia gravis in Japan. In: Annals of the New York Academy of Sciences. 2018.
@article{8d4eac2f602240b18c60acbf7ae17cef,
title = "Rationale for the clinical guidelines for myasthenia gravis in Japan",
abstract = "According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients' health-related quality of life. Therefore, the initial treatment goal is defined as maintaining a postintervention status of minimal manifestations or better (according to the Myasthenia Gravis Foundation of America classification) with an oral prednisolone dose of 5 mg/day or less. Every effort should be made to attain this level as rapidly as possible. To achieve this goal, the guidelines recommend minimizing the oral prednisolone dose, starting calcineurin inhibitors early in the course of treatment, using intravenous methylprednisolone infusion judiciously (often combined with plasma exchange/plasmapheresis or intravenous immunoglobulin), and effectively treating patients with an early, fast-acting treatment strategy. The early, fast-acting treatment strategy enables more frequent and earlier attainment of the initial goal than other strategies. Thymectomy is considered an option for treating nonthymomatous early-onset myasthenia gravis in patients with antiacetylcholine receptor antibodies and thymic hyperplasia in the early stages of the disease.",
keywords = "Clinical guidelines, Corticosteroids, Immunosuppressants, Myasthenia gravis, Thymectomy",
author = "Hiroyuki Murai and Kimiaki Utsugisawa and Yuriko Nagane and Shigeaki Suzuki and Tomihiro Imai and Masakatsu Motomura",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/nyas.13544",
language = "English",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Rationale for the clinical guidelines for myasthenia gravis in Japan

AU - Murai, Hiroyuki

AU - Utsugisawa, Kimiaki

AU - Nagane, Yuriko

AU - Suzuki, Shigeaki

AU - Imai, Tomihiro

AU - Motomura, Masakatsu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients' health-related quality of life. Therefore, the initial treatment goal is defined as maintaining a postintervention status of minimal manifestations or better (according to the Myasthenia Gravis Foundation of America classification) with an oral prednisolone dose of 5 mg/day or less. Every effort should be made to attain this level as rapidly as possible. To achieve this goal, the guidelines recommend minimizing the oral prednisolone dose, starting calcineurin inhibitors early in the course of treatment, using intravenous methylprednisolone infusion judiciously (often combined with plasma exchange/plasmapheresis or intravenous immunoglobulin), and effectively treating patients with an early, fast-acting treatment strategy. The early, fast-acting treatment strategy enables more frequent and earlier attainment of the initial goal than other strategies. Thymectomy is considered an option for treating nonthymomatous early-onset myasthenia gravis in patients with antiacetylcholine receptor antibodies and thymic hyperplasia in the early stages of the disease.

AB - According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients' health-related quality of life. Therefore, the initial treatment goal is defined as maintaining a postintervention status of minimal manifestations or better (according to the Myasthenia Gravis Foundation of America classification) with an oral prednisolone dose of 5 mg/day or less. Every effort should be made to attain this level as rapidly as possible. To achieve this goal, the guidelines recommend minimizing the oral prednisolone dose, starting calcineurin inhibitors early in the course of treatment, using intravenous methylprednisolone infusion judiciously (often combined with plasma exchange/plasmapheresis or intravenous immunoglobulin), and effectively treating patients with an early, fast-acting treatment strategy. The early, fast-acting treatment strategy enables more frequent and earlier attainment of the initial goal than other strategies. Thymectomy is considered an option for treating nonthymomatous early-onset myasthenia gravis in patients with antiacetylcholine receptor antibodies and thymic hyperplasia in the early stages of the disease.

KW - Clinical guidelines

KW - Corticosteroids

KW - Immunosuppressants

KW - Myasthenia gravis

KW - Thymectomy

UR - http://www.scopus.com/inward/record.url?scp=85041093423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041093423&partnerID=8YFLogxK

U2 - 10.1111/nyas.13544

DO - 10.1111/nyas.13544

M3 - Article

C2 - 29377151

AN - SCOPUS:85041093423

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -